Reduction in Insulin Dose Following Shift from Biphasic Human Insulin to Biphasic Insulin Aspart30/70: Experience from Indian-Cohort of IMPROVE™ Study

被引：0

作者：

Shah, Siddharth

Banerjee, Samar

Lamba, P. S.

Chakkarwar, Praful N.

Prusty, Vinay

Moharana, Ashok Kumar

Mazumdar, Anirban

机构：

来源：

DIABETES | 2009年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A534 / A535

页数：2

共 50 条

[21] Biphasic insulin aspart 30 (BIAsp 30) in clinical reality: Experience from a Dutch practice
Ligthelm, Robert J.
[J]. DIABETES, 2007, 56 : A540 - A540
[22] Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70
Heise, T
Kapitza, C
Jacobsen, LV
Brondsted, L
Heinemann, L
[J]. DIABETOLOGIA, 2005, 48 : A301 - A301
[23] A Comparison of Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30, 50, 70 and Pure Insulin Aspart: A Randomized, Quadruple Crossover Study
Thorisdottir, Rannveig Linda
Parkner, Tina
Chen, Jian-Wen
Ejskjaer, Niels
Christiansen, Jens Sandahl
[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (03) : 216 - 221
[24] Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
Heise, Tim
Heinemann, Lutz
Hovelmann, Ulrike
Brauns, Bianca
Nosek, Leszek
Haahr, Hanne L.
Olsen, Klaus J.
[J]. DIABETES CARE, 2009, 32 (08) : 1431 - 1433
[25] GLYCAEMIC CONTROL AND INSULIN UTILIZATION IN UK PATIENTS WITH TYPE 2 DIABETES INITIATED ON EITHER BIPHASIC INSULIN ASPART 30 OR BIPHASIC HUMAN INSULIN 30
Fakhoury, W.
Richter, H.
Christensen, T.
Thomsen, T. L.
Irwin, D.
Anderson, P.
[J]. VALUE IN HEALTH, 2010, 13 (03) : A55 - A55
[26] Efficacy, insulin dose and antibody formation in a four-year trial comparing twice daily biphasic insulin aspart 30 with twice daily biphasic human insulin
Boehm, BO
Keiding, J
Home, P
Raastam, J
[J]. DIABETOLOGIA, 2004, 47 : A274 - A275
[27] An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes
Gupta, Vishal
Baabbad, Ranya
Hammerby, Eva
Nikolajsen, Annie
Shafie, Asrul Akmal
[J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 263 - 272
[28] Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1chieve study
Almansari, A.
Khader, S.
Kharawagh, A.
AbdelFattah, W.
Badawy, T.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (07) : 850 - 856
[29] A comparison of pharmocodynamics and pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in type 1 diabetes
Thorisdottir, Rannveig L.
Parkner, Tina
Chen, Jian-Wen
Ejskjaer, Niels
Christiansen, Jens S.
[J]. DIABETES, 2007, 56 : A555 - A555
[30] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
Liebl, Andreas
Prager, Rudolf
Kaiser, Marcel
Binz, Katharina
Gallwitz, Baptist
[J]. DIABETES, 2006, 55 : A460 - A461

← 1 2 3 4 5 →